Dr. Stegmaier is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney Street
Boston, MA 02115Phone+1 617-632-4985Fax+1 617-632-4850
Education & Training
- Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1999 - 2002
- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1996 - 1999
- Harvard Medical SchoolClass of 1996
Certifications & Licensure
- MA State Medical License 1999 - 2026
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
- Super Doctor SuperDoctors.com
Clinical Trials
- Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma Start of enrollment: 2007 May 01
Publications & Presentations
PubMed
- Targeting the Sodium-Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia.Constanze Schneider, Hermes Spaink, Gabriela Alexe, Neekesh V Dharia, Ashleigh Meyer
Cancer Research. 2024-10-15 - 6 citationsNucleotide depletion promotes cell fate transitions by inducing DNA replication stress.Brian T Do, Peggy P Hsu, Sidney Y Vermeulen, Zhishan Wang, Taghreed Hirz
Developmental Cell. 2024-08-19 - 6 citationsPharmacological targeting of the cancer epigenome.Nathaniel W Mabe, Jennifer A Perry, Clare F Malone, Kimberly Stegmaier
Nature Cancer. 2024-06-01
Journal Articles
- Creatine Kinase Pathway Inhibition Alters GSK3 and WNT Signaling in EVI1-Positive AMLKimberly Stegmaier, MD, Nature
- Selective Gene Dependencies in MYCN-Amplified Neuroblastoma Include the Core Transcriptional Regulatory CircuitryWilliam C Hahn, Todd R Golub, A Thomas Look, Adam D Durbin, Neekesh V Dharia, Kimberly Stegmaier, Nature
- Genome-Scale CRISPR-Cas9 Screen Identifies Druggable Dependencies in TP53 Wild-Type Ewing SarcomaLoren D. Walensky, Kimberly Stegmaier, The Journal of Experimental Medicine
- Join now to see all
Abstracts/Posters
- Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520Kimberly Stegmaier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid LeukemiaKimberly Stegmaier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Core Transcriptional Regulatory Circuitries in AMLKimberly Stegmaier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Drugging the Undruggable61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- What Causes Childhood Cancer, and How Are Researchers Helping?September 19th, 2024
- ETV6 Protein Could Be an Important Target for Ewing Sarcoma TreatmentMarch 7th, 2023
- Routing Cancer Cells to the Right Path May Boost TreatmentJuly 11th, 2022
- Join now to see all
Grant Support
- Targeting The ETS Transcription Factor Rearrangement EWS/FLI In Ewing'S SarcomaNational Institute On Drug Abuse2012
- Validating SYK As A Target For AML TherapyNational Cancer Institute2009–2012
- Chemical Genomics Approach To Leukemia DifferentiationNational Cancer Institute2003–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: